Spots Global Cancer Trial Database for A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
Official Title: A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
Study ID: NCT06095089
Conditions
Study Description
Brief Summary: The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, United States
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
Centre Leon Berard, Lyon, , France
Institut Gustave Roussy, Villejuif, , France
Contact Details
Name: Janssen Research & Development, LLC Clinical Trial
Affiliation: Janssen Research & Development, LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
